Skip to main content
OpenTrials
Completed

NCT Number: NCT05100368

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcoma, Ewing Neoplasms Neoplasms by Histologic Type Neoplasms, Bone Tissue Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Osteosarcoma Sarcoma

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istituto Ortopedico Rizzoli

Bologna, 40136, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis;
  • Patients with age ≥ 2 years;
  • Minimum follow-up duration of 2 years;
  • Medical records, complete blood work and instrumental examinations; Regular follow-up.

Exclusion criteria

  • Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.

Treatment and study plan

Patients

Other

Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis

Primary outcomes

  1. 5-year survival

    Time frame: at baseline (Day0)

    Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental laboratory, clinical and instrumental factors

Secondary outcomes

  1. Rate of local recurrence

    Time frame: at baseline (Day0)

    Evaluation of the rate of local recurrence and distant metastasis in relation to prognostic factors histological, laboratory, clinical and instrumental factors;

Sponsors and collaborators

Lead sponsor

Istituto Ortopedico Rizzoli

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Oct 29, 2021
Registry last updated
Jul 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.